Phio Historical Income Statement
| PHIO Stock | USD 2.64 0.13 5.18% |
Historical analysis of Phio Pharmaceuticals income statement accounts such as Total Operating Expenses of 8.6 M, Income Tax Expense of 214.2 K, Selling General Administrative of 4.2 M or Total Revenue of 0.0 can show how well Phio Pharmaceuticals Corp performed in making a profits. Evaluating Phio Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Phio Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Phio Pharmaceuticals Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Phio Pharmaceuticals Corp is a good buy for the upcoming year.
Phio |
About Phio Income Statement Analysis
Phio Pharmaceuticals Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Phio Pharmaceuticals shareholders. The income statement also shows Phio investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Phio Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Phio Pharmaceuticals Corp. It is also known as Phio Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Most accounts from Phio Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Phio Pharmaceuticals Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. At this time, Phio Pharmaceuticals' Interest Expense is very stable compared to the past year. As of the 28th of November 2024, Total Operating Expenses is likely to grow to about 8.6 M, while Depreciation And Amortization is likely to drop about 125.1 K.
| 2023 | 2024 (projected) | Reconciled Depreciation | 187K | 117.1K | Non Recurring | 4.2M | 3.8M |
Phio Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Phio Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Phio Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 67K | 183K | 75K | 193K | 184K | 125.1K | |
| Other Operating Expenses | 9.0M | 8.8M | 13.5M | 11.5M | 10.8M | 9.0M | |
| Operating Income | (9.0M) | (8.8M) | (13.5M) | (11.5M) | (10.8M) | (11.4M) | |
| Ebit | (9.0M) | (8.9M) | (13.5M) | (11.5M) | (10.8M) | (11.4M) | |
| Research Development | 4.3M | 4.4M | 8.9M | 7.0M | 6.3M | 5.7M | |
| Ebitda | (8.9M) | (8.7M) | (13.4M) | (11.3M) | (10.6M) | (11.2M) | |
| Total Operating Expenses | 9.0M | 8.8M | 13.5M | 11.5M | 4.5M | 8.6M | |
| Income Before Tax | (8.9M) | (8.8M) | (13.3M) | (11.5M) | (10.8M) | (11.4M) | |
| Total Other Income Expense Net | 4K | 79K | (1K) | 224K | (18K) | (2.1K) | |
| Net Income | (8.8M) | (8.8M) | (13.2M) | (11.3M) | (10.8M) | (11.4M) | |
| Income Tax Expense | (67K) | (134.3K) | (75K) | (175K) | 204K | 214.2K | |
| Selling General Administrative | 4.7M | 4.4M | 4.6M | 4.5M | 4.3M | 4.2M | |
| Gross Profit | 21K | (183K) | (192K) | (193K) | (6.3M) | (6.0M) | |
| Cost Of Revenue | 4.3M | 183K | 192K | 193K | 6.3M | 4.3M | |
| Net Income From Continuing Ops | (8.9M) | (8.8M) | (13.3M) | (11.5M) | (11.7M) | (12.2M) | |
| Net Income Applicable To Common Shares | (7.4M) | (8.9M) | (8.8M) | (13.3M) | (15.3M) | (16.0M) | |
| Reconciled Depreciation | 67K | 72K | 75K | 193K | 187K | 117.1K |
Pair Trading with Phio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Phio Stock
| 0.57 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.52 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.37 | ESLAW | Estrella Immunopharma | PairCorr |
The ability to find closely correlated positions to Phio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phio Pharmaceuticals Corp to buy it.
The correlation of Phio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phio Pharmaceuticals Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Phio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.81) | Return On Assets (0.61) | Return On Equity (1.27) |
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.